-
Antagonizing roles of SHP1 in the pathogenesis of Helicobacter pylori infection Helicobacter (IF 4.4) Pub Date : 2024-03-12 Si Chen, Huilin Zhao, Yue Tian, Qianwen Wu, Jianhui Zhang, Shuzhen Liu, Ying Zhang, Yulong Wu, Boqing Li, Shu Chen, Zhiqiang Wang, Ruoyu Xiao, Xiaofei Ji
BackgroundSHP1 has been documented as a tumor suppressor and it was thought to play an antagonistic role in the pathogenesis of Helicobacter pylori infection. In this study, the exact mechanism of this antagonistic action was studied.Materials and MethodsAGS, MGC803, and GES‐1 cells were infected with H. pylori, intracellular distribution changes of SHP1 were first detected by immunofluorescence. SHP1
-
Impact of mixed‐infection rate of clarithromycin‐susceptible and clarithromycin‐resistant Helicobacter pylori strains on the success rate of clarithromycin‐based eradication treatment Helicobacter (IF 4.4) Pub Date : 2024-03-09 Momoko Tsuda, Yoshiyuki Watanabe, Ritsuko Oikawa, Ryosuke Watanabe, Masayuki Higashino, Kimitoshi Kubo, Hiroyuki Yamamoto, Fumio Itoh, Mototsugu Kato
BackgroundClarithromycin (CAM) resistance is a major contributor to the failure to eradicate Helicobacter pylori (H. pylori). The mixed‐infection ratio of CAM‐susceptible and CAM‐resistant H. pylori strains differs among individuals. Pyrosequencing analysis can be used to quantify gene mutations at position each 2142 and 2143 of the H. pylori 23S rRNA gene in intragastric fluid samples. Herein, we
-
Volatilomic signatures of different strains of Helicobacter pylori Helicobacter (IF 4.4) Pub Date : 2024-03-09 Reinis Vangravs, Linda Mežmale, Daria Ślefarska‐Wolak, Edgars Dauss, Clemens Ager, Alejandro H. Corvalan, Elmer Andrés Fernández, Chris A. Mayhew, Marcis Leja, Paweł Mochalski
BackgroundHelicobacter pylori (H. pylori) infection is the most extensively studied risk factor for gastric cancer. As with any bacteria, H. pylori will release distinctive odors that result from an emission of volatile metabolic byproducts in unique combinations and proportions. Effectively capturing and identifying these volatiles can pave the way for the development of innovative and non‐invasive
-
Meta‐analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy Helicobacter (IF 4.4) Pub Date : 2024-03-06 Hui Yang, Miao Zhang, Gang Ma, Jiaqi Yang, Kemei Wang, Shuangshuang Jiang, Jiaqiang Dong, Ying Han
BackgroundVonoprazan, a novel acid suppressant, has recently emerged as a regimen for eradicating Helicobacter pylori. However, uncertainties exist about the effectiveness and safety of VPZ‐based regimens compared with those of bismuth‐based quadruple therapy in eradicating H. pylori. The present meta‐analysis was performed to compare the effectiveness and safety of vonoprazan‐based regimens with those
-
Disruption of the gastric epithelial barrier in Correa's cascade: Clinical evidence via confocal endomicroscopy Helicobacter (IF 4.4) Pub Date : 2024-03-06 Shao‐Tong Wang, Hua‐Wei Yang, Wen‐Lin Zhang, Zhen Li, Rui Ji
BackgroundGastric epithelial barrier disruption constitutes a crucial step in gastric cancer (GC). We investigated these disruptions during the Correa's cascade timeline to correlate epithelial barrier dysfunction.Materials and MethodsThis study was conducted as a single‐center, non‐randomized clinical trial in China from May 2019 to October 2022. Patients with chronic atrophic gastritis (CAG), gastric
-
-
Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review Helicobacter (IF 4.4) Pub Date : 2024-02-28 Spriha Dutta, Surbhi Jain, Kunal Das, Prashant Verma, Anup Som, Rajashree Das
BackgroundHelicobacter pylori antibiotic resistance has undergone vast changes in the last two decades. No systematic review has been done on the prevalence of antibiotic resistant H. pylori in India in the last two decades. We evaluated the pattern of resistance rates across various regions of India.Materials and MethodsA systematic review of the geographical variations in antibiotic resistance pattern
-
A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran Helicobacter (IF 4.4) Pub Date : 2024-02-27 Sepehr Tirgar Fakheri, Hajar Shokri‐Afra, David Y. Graham, Zohreh Bari, Hafez Fakheri
BackgroundHelicobacter pylori (H. pylori) is strongly associated with peptic ulcer disease and gastric cancer. We evaluated two triple therapy regimens comprising esomeprazole, high dose bismuth, and different doses of amoxicillin for first‐line H. pylori eradication.Materials and MethodsTwo hundred patients with dyspepsia and naive H. pylori infection were randomly assigned into two groups (n = 100)
-
Comparison between the GastroPanel test and the serum pepsinogen assay interpreted with the ABC method—A prospective study Helicobacter (IF 4.4) Pub Date : 2024-02-25 Sun‐Young Lee, Yeon‐Sun Ahn, Hee‐Won Moon
Background and AimsThis study aimed to validate Helicobacter pylori serological and pepsinogen (PG) assays for detecting infection and gastric neoplasm.MethodsIndividuals who underwent serum Chorus H. pylori and HBI PG assays were included from May to September 2023. The GastroPanel test was performed using the same blood sample. HBI assay findings were interpreted with the ABC method using the criteria
-
Helicobacter pylori antigens as immunomodulators of immune system Helicobacter (IF 4.4) Pub Date : 2024-02-21 Zeynab Marzhoseyni, Mohammad Javad Mousavi, Somayeh Ghotloo
Helicobacter pylori (H. pylori) is one of the most prevalent human pathogens and the leading cause of chronic infection in almost half of the population in the world (~59%). The bacterium is a major leading cause of chronic gastritis, gastric and duodenal ulcers, and two type of malignancies, gastric adenocarcinoma and mucosa‐associated lymphoid tissue (MALT) lymphoma. Despite the immune responses
-
Helicobacter hepaticus and Helicobacter bilis in liver and biliary cancers from ATBC and PLCO Helicobacter (IF 4.4) Pub Date : 2024-02-08 Gwen Murphy, Neal D. Freedman, Christian C. Abnet, Demetrius Albanes, Amanda J. Cross, Wen-Yi Huang, Jill Koshiol, Katherine McGlynn, Dominick Parisi, Satu Männistö, Stephanie J. Weinstein, Tim Waterboer, Julia Butt
Helicobacter species (spp.) have been detected in human bile and hepatobiliary tissue Helicobacter spp. promote gallstone formation and hepatobiliary tumors in laboratory studies, though it remains unclear whether Helicobacter spp. contribute to these cancers in humans. We used a multiplex panel to assess whether seropositivity to Helicobacter (H.) hepaticus or H. bilis proteins was associated with
-
Machine learning models in predicting failure of Helicobacter pylori treatment: A two country validation study Helicobacter (IF 4.4) Pub Date : 2024-01-25 Fang Jiang, Thomas K. L. Lui, Chengsheng Ju, Chuan-Guo Guo, Ka Shing Cheung, Wallis C. Y. Lau, Wai K. Leung
The success rate of clarithromycin-containing Helicobacter pylori treatment had declined globally. This study aims to explore the role of different machine learning algorithms in predicting failure of H. pylori treatment.
-
Helicobacter pylori infection and inflammasomes Helicobacter (IF 4.4) Pub Date : 2024-01-24 Huiling Zheng, Pengyan Xia, Weiwei Fu, Shigang Ding
Helicobacter pylori (H. pylori) causes the most prevalent bacterial infection worldwide, and more than half of the world's population is infected with H. pylori. Classified as a group 1 carcinogen of gastric cancer, H. pylori infection causes the most common chronic gastritis, which is able to progress to chronic atrophic gastritis, dysplasia, and even gastric cancer. The inflammasomes are important
-
Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial Helicobacter (IF 4.4) Pub Date : 2024-01-24 Yi Hu, Xiang-Hua Huang, Bo Zhou, Meng-Lan Liu, Ye-Fei Liu, Tao Yu, Ping Sun, Bin-Bin Tan, Yang Hu, Fei Cheng, Xiao-Lin Pan, Jun-Bo Hong, Xu Shu, Yin Zhu, Nong-Hua Lu
We previously optimized the duration and dose of vonoprazan and amoxicillin dual therapy in China. The efficacy of vonoprazan with b.i.d. amoxicillin in comparison with vonoprazan-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection has not been adequately evaluated.
-
Gastric Helicobacter pylori infection does not contribute to extraoral halitosis and its eradication cannot achieve substantial reduction of halitosis Helicobacter (IF 4.4) Pub Date : 2024-01-24 Ying Chen, Xiao Xian Qian
Some researchers have suggested that Helicobacter pylori (H. pylori) infection is attributed to extraoral halitosis. However, this viewpoint is increasingly challenged by clinical practice. This study was conducted with the aim of investigating changes of extraoral halitosis before and after H. pylori eradication.
-
Risk of map-like redness development after eradication therapy for Helicobacter pylori infection Helicobacter (IF 4.4) Pub Date : 2024-01-24 Sho Matsumoto, Mitsushige Sugimoto, Masakatsu Fukuzawa, Nana Uesugi, Eri Iwata, Yasuyuki Kagawa, Akira Madarame, Yohei Koyama, Takashi Morise, Kumiko Uchida, Hayato Yamaguchi, Shin Kono, Sakiko Naito, Takashi Kawai, Takao Itoi
Map-like redness is a newly identified endoscopic risk factor for gastric cancer in patients who received Helicobacter pylori eradication therapy. However, the incidence rate of map-like redness in patients who received eradication, and the risk factors for the development of map-like redness remain unclear. We hence aimed to investigate the incidence rate of map-like redness at 1-year post H. pylori
-
Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review Helicobacter (IF 4.4) Pub Date : 2024-01-24 Xiaoqi Wu, Miao Duan, Qingzhou Kong, Shuyan Zeng, Leiqi Xu, Yueyue Li, Xiaoyun Yang, Xiuli Zuo
Current global variations exist in Helicobacter pylori (H. pylori) eradication regimens. Triple therapy (TT), bismuth quadruple therapy (BQT), and high-dose dual therapy (HDDT) currently represent the predominant regimens. These regimens diverge in terms of treatment duration, the utilization of susceptibility testing, acid-inhibiting drug administration, and patient education. We conducted a comprehensive
-
Seroprevalence of Helicobacter pylori infection among schoolchildren in southern Taiwan—A 20-year longitudinal follow-up Helicobacter (IF 4.4) Pub Date : 2024-01-24 Hsiao-Yu Lo, Yao-Jong Yang
Helicobacter pylori infection is primarily acquired in childhood and can lead to peptic ulcer diseases and gastric cancer. The prevalence of H. pylori infection varies widely in different countries. The aim of this study was to explore the change of pediatric H. pylori seroprevalence in the past two decades and to investigate the risk factors for pediatric H. pylori seropositivity in southern Taiwan
-
Paving the way for a non-antibiotic and microbiota friendly therapy for Helicobacter pylori: In vitro and in vivo performance of lipid nanoparticles Helicobacter (IF 4.4) Pub Date : 2024-01-24 Catarina Leal Seabra, A. Sofia Pinho, Cláudia Nunes, Irina Amorim, Nicole Pedro, Patrícia Henriques, Cláudia Monteiro, Joana Gomes, Cláudia Machado, Fátima Gartner, Luísa Pereira, Salette Reis, Celso A. Reis, Eliette Touati, Inês C. Gonçalves, Paula Parreira, M. Cristina L. Martins
The World Health Organization has identified Helicobacter pylori, a Gram-negative bacterium responsible for several gastric disorders, as one of the pathogenic bacteria that requires newer non-antibiotic approaches for its management. We previously demonstrated that nanostructured lipid carriers (NLC) loaded with docosahexaenoic acid (DHA-NLC) have excellent in vitro performance against H. pylori.
-
Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis Helicobacter (IF 4.4) Pub Date : 2023-11-30 Ren-Chun Du, Yu-Xin Hu, Yaobin Ouyang, Li-Xiang Ling, Jing-Yuan Xu, Rina Sa, Xiao-Shun Liu, Jun-Bo Hong, Yin Zhu, Nong-Hua Lu, Yi Hu
Recent clinical trials have evaluated the efficacy of vonoprazan-amoxicillin (VA) dual therapy as the first-line treatment for Helicobacter pylori infection in different regions with inconsistent results reported. In this systematic review and meta-analysis, we aimed to evaluate the efficacy of VA dual therapy compared to the currently recommended therapy for eradicating H. pylori.
-
Do atrophic gastritis and intestinal metaplasia reverse after Helicobacter pylori eradication? Helicobacter (IF 4.4) Pub Date : 2023-11-29 Yongqiang Liang, Yuanhai Yang, Ruiheng Nong, Hao Huang, Xiuyun Chen, Ying Deng, Zhicong Huang, Jingyao Huang, Chunsheng Cheng, Mingzhu Ji, Yinggang Chen, Fulan Hu
It's still controversial whether Helicobacter pylori (H. pylori) eradication can reverse atrophic gastritis (AG) and intestinal metaplasia (IM). Therefore, we performed a meta-analysis to estimate the effect of H. pylori eradication on AG and IM.
-
The association between Helicobacter pylori and gastrointestinal disorders during pregnancy: A Multicenter retrospective study Helicobacter (IF 4.4) Pub Date : 2023-11-27 Yun Feng, Qing Huang, Miaosha Luo, Jia Wei, Tiantian Gao, Dake Chu, Ai Jia, Yingchao Li, Shuixiang He, Tianjiao Duan
Some gastrointestinal disorders may be associated with Helicobacter pylori infection, which not only affect maternal health, but may also lead to adverse pregnancy outcomes. We aim to explore the association between H. pylori and gastrointestinal disorders in pregnant women.
-
Transcriptomic remodeling of gastric cells by Helicobacter pylori outer membrane vesicles Helicobacter (IF 4.4) Pub Date : 2023-11-23 Joana Melo, Bruno Cavadas, Luísa Pereira, Ceu Figueiredo, Marina Leite
Outer membrane vesicles (OMVs) are spontaneously released by Gram-negative bacteria and influence bacteria-host interactions by acting as a delivery system for bacterial components and by interacting directly with host cells. Helicobacter pylori, a pathogenic bacterium that chronically colonizes the human stomach, also sheds OMVs, and their impact on bacterial-mediated diseases is still being elucidated
-
-
Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis Helicobacter (IF 4.4) Pub Date : 2023-11-20 Ben-Gang Zhou, Xin Jiang, Yan-Bing Ding, Qiang She, Yao-Yao Li
Recently, vonoprazan-amoxicillin (VA) dual therapy has been reported as a promising approach for Helicobacter pylori (H. pylori) eradication. However, the effects of VA therapy versus bismuth-containing quadruple therapy (BQT) on H. pylori eradication remains unclear. The objective of this meta-analysis was to compare the effects of VA dual therapy with BQT for H. pylori eradication.
-
Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients Helicobacter (IF 4.4) Pub Date : 2023-11-20 Na Rae Lim, Jiyoung Kim, Woo Chul Chung
Helicobacter pylori (H. pylori) infections can recur as either recrudescence or reinfection. At a time when the decline in the eradication rate is becoming evident, increases in the rate of recurrence are concerning. In addition, there are no guidelines for selecting an eradication regimen for H. pylori recurrence.
-
Profile of Helicobacter pylori infections among children in the South Island of New Zealand (2010–2021) Helicobacter (IF 4.4) Pub Date : 2023-11-20 Angharad Vernon-Roberts, Malshi Premaratne, Raewyn Wright, Jacqueline I. Keenan, Andrew S. Day
Helicobacter pylori is a gram-negative gut bacterium most often acquired during childhood. International guidelines state that children with suspected H. pylori infection should be referred to a gastroenterologist for investigation via gastroscopy and biopsy. Eradication therapy should be prescribed for children with peptic ulcer disease or following a treatment risk/benefit discussion for those with
-
Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter study from 2016 to 2023 Helicobacter (IF 4.4) Pub Date : 2023-11-20 Wenyan Xu, Bite Yang, Lang Lin, Qiong Lin, Hui Wang, Lu Yang, Zhongyue Li, Shelby Lamm, Ye Chen, Ningmin Yang, Yishu Chen, Chaohui Yu, Lan Li
To investigate the antibiotic resistance of Helicobacter pylori (H. pylori) strains to clarithromycin, metronidazole, amoxicillin, levofloxacin, furazolidone, and tetracycline in Chinese children.
-
Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants—A review Helicobacter (IF 4.4) Pub Date : 2023-11-16 Kuang Yunle, Wu Tong, Liu Jiyang, Wu Guojun
Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that infects approximately 50% of the world's population and has been strongly associated with chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoma, and gastric cancer. The elimination of H. pylori is currently considered one of the most effective strategies for the treatment of gastric-related diseases, so antibiotic therapy
-
Letter to the Editor regarding the article: "Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy". Helicobacter (IF 4.4) Pub Date : 2023-11-13 Tsolaki Fani,Tagarakis G Ioannis
-
The nonadherence and risk factors of eradication failure by sequential therapy as first-line anti-Helicobacter pylori treatment in real-world clinical practice Helicobacter (IF 4.4) Pub Date : 2023-11-10 Chun-Te Lee, Chung-Tai Wu, Wei-Lun Chang, Er-Hsiang Yang, Ming-Tsung Hsieh, Wei-Ying Chen, Bor-Shyang Sheu, Hsiu-Chi Cheng
The eradication rates of sequential therapy are high in clinical trials; however, the adherence for follow-up or the patient population in a real-world setting might be different from those in trails. This study investigates the effectiveness of sequential therapy in a real-world setting and the factors that lead to treatment failure.
-
Interactions between Helicobacter pylori infection and host metabolic homeostasis: A comprehensive review Helicobacter (IF 4.4) Pub Date : 2023-10-23 Junzhao Ye, Ting Feng, Lei Su, Jin Li, Yingying Gong, Xiaoyi Ma
The microbiota actively and extensively participates in the regulation of human metabolism, playing a crucial role in the development of metabolic diseases. Helicobacter pylori (H. pylori), when colonizing gastric epithelial cells, not only induces local tissue inflammation or malignant transformation but also leads to systemic and partial changes in host metabolism. These shifts can be mediated through
-
Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs Helicobacter (IF 4.4) Pub Date : 2023-10-15 Wenwen Gao, Mingliang Zhu, Yanhui Yin, Xiang Zhang, Lu Wang
The effective regimen is lacking in areas with high antibiotic resistance and tetracycline unavailable. Whether minocycline can replace tetracycline for Helicobacter pylori eradication is unknown. This meta-analysis compared and summarized the efficacy and safety profiles of H. pylori quadruple regimens with and without minocycline.
-
Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation Helicobacter (IF 4.4) Pub Date : 2023-10-15 Mahmood Yousefi, Satar Rezaei, Manouchehr Khoshbaten, Maryam Sarmasti
The World Health Organization recommends assessing screening for helicobacter pylori infection to lower gastric cancer (GC) rates. Therefore, we carried out a study to evaluate the cost-effectiveness of different H. pylori screening approaches in Iran.
-
Antimicrobial-resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018–2020 Helicobacter (IF 4.4) Pub Date : 2023-10-12 Tadayoshi Okimoto, Takashi Ando, Makoto Sasaki, Shoko Ono, Intetsu Kobayashi, Keigo Shibayama, Daisuke Chinda, Kengo Tokunaga, Shigemi Nakajima, Takako Osaki, Toshiro Sugiyama, Mototsugu Kato, Kazunari Murakami
Antimicrobial therapy is necessary to eradicate Helicobacter pylori infection. The emergence of antimicrobial-resistant bacteria poses a threat to continued treatment with antimicrobial agents. For those who prescribe antimicrobial therapy, it is necessary to constantly monitor the emergence of antimicrobial-resistant bacteria.
-
Information quality of videos related to Helicobacter pylori infection on TikTok: Cross-sectional study Helicobacter (IF 4.4) Pub Date : 2023-10-12 Wei Tan, Yilong Liu, Zhiwen Shi, Bainan Zheng, Lingmei Feng, Jian Wang, Xiaohang Wang, Zongli Yuan
Helicobacter pylori (H. pylori) poses serious threats to human health. TikTok (Douyin in Chinese), a major social media platform focused on sharing short videos, has demonstrated great potential in spreading health information, including information related to H. pylori infection. This study aims to evaluate the content and quality of the information shared in TikTok videos about H. pylori infection
-
Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy Helicobacter (IF 4.4) Pub Date : 2023-10-11 Humphrey J. O'Connor
It is 40 years since the discovery of Helicobacter pylori infection. Over that time major changes have occurred in esophagogastroduodenoscopy (EGD) findings. The aim of this review is to describe these changes, and the important role H. pylori infection has played in their evolution.
-
Reactive oxygen species and gastric carcinogenesis: The complex interaction between Helicobacter pylori and host Helicobacter (IF 4.4) Pub Date : 2023-10-05 Shiying Wu, Yongqiang Chen, Ziqi Chen, Fangtong Wei, Qingqing Zhou, Ping Li, Qing Gu
Helicobacter pylori (H. pylori) is a highly successful human pathogen that colonizes stomach in around 50% of the global population. The colonization of bacterium induces an inflammatory response and a substantial rise in the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), mostly derived from host neutrophils and gastric epithelial cells, which play a crucial role in
-
Helicobacter pylori infection and rheumatoid arthritis as risk enhancers' factors for atherosclerotic cardiovascular diseases Helicobacter (IF 4.4) Pub Date : 2023-10-04 Maria Pina Dore, Gian Luca Erre, Jessica Piroddu, Giovanni Mario Pes
In addition to established risk factors for atherosclerotic cardiovascular diseases (aCVDs), infections and autoimmune diseases, such as Helicobacter pylori (H. pylori) and rheumatoid arthritis (RA), have been reported as risk–enhancer factors. In this retrospective single-center, case–control study, the relative weight of RA and H. pylori infection on aCVD was evaluated in a cohort of patients from
-
Helicobacter pylori virulence genotypes in Bogotá River and wastewater treatment plants in Colombia Helicobacter (IF 4.4) Pub Date : 2023-09-27 Fidson-Juarismy Vesga, Adriana Rocío Beltrán-Benavides, Ana María Márquez-Duque, Camilo Venegas, Alba-Alicia Trespalacios
Helicobacter pylori is a bacterium that infects 70%–80% of the population in Colombia, causing chronic gastritis in all those infected and gastric cancer in 1%–2% of those infected. In Colombia, some studies have identified the presence of vacA and cagA genes in environmental samples such as treated, surface, and wastewater, but they have not been evaluated in the Bogotá River. For this, the aim of
-
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan Helicobacter (IF 4.4) Pub Date : 2023-09-18 Sarita Ratana-Amornpin, Likasith Sanglutong, Thanee Eiamsitrakoon, Sith Siramolpiwat, David Y. Graham, Varocha Mahachai
Vonoprazan-containing Helicobacter pylori eradication is reliably effective in Japan. Its effectiveness in other countries remains unclear. Here, we examined vonoprazan-H. pylori therapies in Thailand.
-
Research trends on the relationship between Helicobacter pylori and microbiota: A bibliometric analysis Helicobacter (IF 4.4) Pub Date : 2023-09-11 Yu Li, Yaobin Ouyang, Cong He
Increasing evidence has indicated that Helicobacter pylori infection is associated with the complex microbiota in the digestive tract of the human body. We aimed to assess the research trends and hotspots in the field of H. pylori and microbiota using a quantitative method.
-
The role of toll-like receptors in immune tolerance induced by Helicobacter pylori infection Helicobacter (IF 4.4) Pub Date : 2023-09-10 Xiulin Zhang, Ke Zhang, Linlin Yan, Pengfei Wang, Fan Zhao, Shoukui Hu
Helicobacter pylori (H. pylori) is a gram-negative, microaerobic bacterium that colonizes the gastric mucosa in about half of the world's population. H. pylori infection can lead to various diseases. Chronic infection by H. pylori exposes the gastric mucosa to bacterial components such as lipopolysaccharide (LPS), outer membrane vesicles (OMVs), and several toxic proteins. Infected with H. pylori activates
-
Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: A systematic review and meta-analysis Helicobacter (IF 4.4) Pub Date : 2023-09-03 Xiaomin Gong, Liting Shen, Jinliang Xie, Dingwei Liu, Yong Xie, Dongsheng Liu
Cancer immunotherapy has shown promising results in several tumors, but its efficacy is influenced by the immune state of the body. Helicobacter pylori (H. pylori) infection can modulate the immune function of the body through various pathways, ultimately affecting the effectiveness of cancer immunotherapy.
-
Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis Helicobacter (IF 4.4) Pub Date : 2023-08-27 Kaihao Lin, Lifang Huang, Yadong Wang, Kangkang Li, Yuanning Ye, Siqi Yang, Aimin Li
The prevalence of antibiotic resistance for Helicobacter pylori (H. pylori) has been increasing over the year, making it more difficult for traditional empirical therapy to successfully eradicate H. pylori. Thus, tailored therapy (TT) guided by molecular-based antibiotic susceptibility testing (AST) has been frequently recommended. We conducted a single-arm meta-analysis to determine the efficacy of
-
Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia Helicobacter (IF 4.4) Pub Date : 2023-08-27 Duc Trong Quach, Ratha-korn Vilaichone, Mai Ngoc Luu, Yeong Yeh Lee, Tiing Leong Ang, Muhammad Miftahussurur, Than Than Aye, Dewi Norwani Basir, Ky Vutha, Sengdao Vannarath, Jose D. Sollano, Varocha Mahachai
Multidrug-resistant Helicobacter pylori strains are emerging in Southeast Asia. This study evaluates the region's real-world practice in H. pylori management.
-
Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice Helicobacter (IF 4.4) Pub Date : 2023-08-25 Zhihao Yu, Xiangyue Zhang, Qiao Zhao, Xin Yan, Chengmeng Wu, Liting Qing, Zongyu He, Qian Chen, Min Huang, Jian Zhao, Mei Cao
Helicobacter pylori is one of the most common chronic bacterial infections. Active eradication of H. pylori infection is rare due to the fact that most infected patients are asymptomatic and the use of large amounts of antibiotics in eradication therapy leads to severe side effects. Urolithin B (UB) is an additional major intestinal metabolite of ellagic acid (EA), which has been shown to possess anti-inflammatory
-
Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial Helicobacter (IF 4.4) Pub Date : 2023-08-23 Nur Izreena Ismail, Khairul Najmi Muhammad Nawawi, Deborah Chew Chia Hsin, Kok Wei Hao, Nik Ritza Kosai Nik Mahmood, Gary Lee Chong Chearn, Zhiqin Wong, Azmi Mohd Tamil, Hazel Joseph, Raja Affendi Raja Ali
Despite multiple therapy regimens, the decline in the Helicobacter pylori eradication rate poses a significant challenge to the medical community. Adding Lactobacillus reuteri probiotic as an adjunct treatment has shown some promising results. This study aims to investigate the efficacy of Lactobacillus reuteri DSM 17648 in H. pylori eradication and its effect in ameliorating gastrointestinal symptoms
-
Effect of Helicobacter pylori eradication on gastric precancerous lesions: A systematic review and meta-analysis Helicobacter (IF 4.4) Pub Date : 2023-08-21 Fangyuan Zhu, Xiaoze Zhang, Ping Li, Yaodong Zhu
The question of whether eradication of Helicobacter pylori (Hp) can reverse gastric precancerous lesions, including intestinal metaplasia, remains uncertain, leading to ongoing debate. Therefore, a meta-analysis was performed to evaluate the effect of Hp eradication on gastric precancerous lesions.
-
Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis Helicobacter (IF 4.4) Pub Date : 2023-08-10 Na-Yun Su, Qing Shi, Hao Mei, Jie Hu, Yu-Xiang Liu, Han-Ning Liu, Heng-Qi Liu, Yan Guo, Xing-wei Wang, Chun-Hui Lan
According to the Maastricht VI/Florence consensus report, potassium-competitive acid blockers (P-CAB) may improve Helicobacter pylori eradication treatment.
-
Helicobacter macacae MazF interplays with Escherichia coli homologs and enhances antibiotic tolerance Helicobacter (IF 4.4) Pub Date : 2023-08-09 Xi Zeng, Limiao Hu, Qi Ai, Cai-Juan Liu, Lu-Xi Xiong, Wei-Wei Yang, Xiaotuan Zhang, Logen Liu, Guo-Qing Li
Toxin-antitoxin systems are highly variable, even among strains of the same bacterial species. The MazEF toxin-antitoxin system is found in many bacteria and plays important roles in various biological processes such as antibiotic tolerance and phage defense. However, no interplay of MazEF systems between different species was reported.
-
Association of Helicobacter pylori with migraine headaches and the effects of this infection and its eradication on the migraine characteristics in adults: A comprehensive systematic review and meta-analysis Helicobacter (IF 4.4) Pub Date : 2023-08-02 Rashed Bawand, Masoud Ghiasian, Mustapha Samadyan, Sorush Qaderi
Migraine is one of the most common neurological disorders that can severely overshadow people's quality of life, and Helicobacter pylori infection is a health problem in different societies. During the last two decades, many original studies have been conducted on the various aspects of the relationship between these two disorders; however, they have reported different and sometimes contradictory results
-
Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023 Helicobacter (IF 4.4) Pub Date : 2023-07-29 Ren-Chun Du, Yao-Bin Ouyang, Nong-Hua Lu, Yi Hu
Vonoprazan is an emerging option for the treatment of Helicobacter pylori infection. We aimed to assess the research trends and hotspots of vonoprazan-based therapy for H. pylori eradication through bibliometric analysis.
-
Genome-wide association study of Helicobacter pylori serological status in Latin American children Helicobacter (IF 4.4) Pub Date : 2023-07-27 Iasmin Souza Lima, Thiago Magalhães da Silva, Stefan Weiss, Georg Homuth, Markus M. Lerch, Camila A. Figueiredo, Neuza Maria Alcantara-Neves, Maurício Lima Barreto, Cintia Rodrigues Marques
Few genome-wide association studies (GWAS) on Helicobacter pylori infection susceptibility have been conducted for admixed populations from developing countries. Here, we performed a GWAS to identify genetic factors associated with H. pylori serostatus in a cohort of admixed children from a large Latin American urban center.
-
Antibiotic resistance and heteroresistance in Helicobacter pylori isolates from symptomatic Vietnamese children: A prospective multicenter study Helicobacter (IF 4.4) Pub Date : 2023-07-27 Tu Cam Nguyen, Giao Kim Ngoc Le, Dao Thi Hong Pham, Bao Van Pham, Loan Thi Hong Nguyen, Thai Hoang Che, Hiep Thanh Nguyen, Dinh Quang Truong, Annie Robert, Patrick Bontems, Phuong Ngoc Van Nguyen
Antibiotic resistance of Helicobacter pylori (H. pylori) is increasing worldwide, with geographical variations, impacting the treatment outcomes. This study assessed the antibiotic resistance patterns of H. pylori in Vietnamese children.
-
TikTok and Bilibili as sources of information on Helicobacter pylori in China: A content and quality analysis Helicobacter (IF 4.4) Pub Date : 2023-07-15 Ren-Chun Du, Yang Zhang, Meng-Hui Wang, Nong-Hua Lu, Yi Hu
Helicobacter pylori (H. pylori) is closely associated with gastric diseases and has a high prevalence in China. Public platforms are considered common and important tools to publicize H. pylori-related information. This study aimed to assess and compare the content and quality of H. pylori-related videos on TikTok and Bilibili.
-
Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children Helicobacter (IF 4.4) Pub Date : 2023-07-04 Kallirroi Kotilea, Eleni Iliadis, Julie Nguyen, Assad Salame, Tania Mahler, Veronique Yvette Miendje Deyi, Patrick Bontems
Antibiotic resistance is a well-known factor of Helicobacter pylori eradication failure. Heteroresistance indicates the coexistence of resistant and susceptible strains and might lead to underestimating antimicrobial resistance. This study aims to evaluate the susceptibility profile, the frequency of heteroresistance of H. pylori strains, and their effect on eradication success in a pediatric population
-
Antimicrobial screening involving Helicobacter pylori of nano-therapeutic compounds based on the amoxicillin antibiotic drug Helicobacter (IF 4.4) Pub Date : 2023-06-30 Safaa S. Hassan, Madonna Nader, Maria Nagy, Mennatallah Mohamed, Mennatulla Nader, Mina Zakaria, Nada Mohamed, Rawan Waleed, Fatma B. Rashidi
Nano-structure Cu(II) complex [Cu(AMAB)2]Cl2 with Schiff base (AMAB) derived from the condensation between 4-(dimethylamino)benzaldehyde and amoxicillin trihydrate was prepared. (AMAB) Schiff base and its Cu(II) complex were identified and confirmed by different physicochemical techniques. The Schiff base (AMAB) was coordinated to copper ion through carbonyl oxygen and imine nitrogen donor sites. X-ray
-
Helicobacter pylori induces urease subunit B-specific CD8+ T cell responses in infected individuals via cytosolic pathway of cross-presentation Helicobacter (IF 4.4) Pub Date : 2023-06-29 Zelin Zhang, Xingchi Chen, Bin Li, Tingting Xia, Xiaobin Wu, Chao Wu
Urease subunit B (UreB), a conserved and key virulence factor of Helicobacter pylori (H. pylori), can induce the host CD4+ T cell immune responses to provide protection, but less is known regarding CD8+ T cell responses. The characteristics of H. pylori-specific CD8+ T cell responses and the mechanism underlying antigen processing and presentation pathways remain unclear. This study was focus on protective
-
The expression and function of the B7 family in Helicobacter pylori infection and gastric carcinogenesis process Helicobacter (IF 4.4) Pub Date : 2023-06-29 Yuan Zhang, Zhenkun Zhao, Weiwei Fu, Shigang Ding
The B7 protein family is one of the most important immune checkpoint proteins. Gastric cancer (GC) is the fourth most common cause of cancer-related mortality worldwide and shows a significant correlation with the B7 family in tumorigenesis and progression. Helicobacter pylori infection is the most important risk factor promoting the progression of gastric precancerous lesions and GC, which also affects